pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-133a-1 |
Genomic Coordinates | chr18: 21825698 - 21825785 |
Synonyms | MIRN133A1, MIR133A1 |
Description | Homo sapiens miR-133a-1 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases | |
pre-miRNA | hsa-mir-133a-2 |
Genomic Coordinates | chr20: 62564912 - 62565013 |
Synonyms | MIRN133A2, MIR133A2 |
Description | Homo sapiens miR-133a-2 stem-loop |
Comment | This miRNA sequence is predicted based on homology to a verified miRNA from mouse . |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-133a-3p | |||||||||||||||||||||||||||
Sequence | 53| UUUGGUCCCCUUCAACCAGCUG |74 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Biomarker Information |
|
---|
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | EGFR | ||||||||||||||||||||
Synonyms | ERBB, ERBB1, HER1, NISBD2, PIG61, mENA | ||||||||||||||||||||
Description | epidermal growth factor receptor | ||||||||||||||||||||
Transcript | NM_005228 | ||||||||||||||||||||
Other Transcripts | NM_201282 , NM_201283 , NM_201284 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on EGFR | |||||||||||||||||||||
3'UTR of EGFR (miRNA target sites are highlighted) |
>EGFR|NM_005228|3'UTR 1 CCACGGAGGATAGTATGAGCCCTAAAAATCCAGACTCTTTCGATACCCAGGACCAAGCCACAGCAGGTCCTCCATCCCAA 81 CAGCCATGCCCGCATTAGCTCTTAGACCCACAGACTGGTTTTGCAACGTTTACACCGACTAGCCAGGAAGTACTTCCACC 161 TCGGGCACATTTTGGGAAGTTGCATTCCTTTGTCTTCAAACTGTGAAGCATTTACAGAAACGCATCCAGCAAGAATATTG 241 TCCCTTTGAGCAGAAATTTATCTTTCAAAGAGGTATATTTGAAAAAAAAAAAAAGTATATGTGAGGATTTTTATTGATTG 321 GGGATCTTGGAGTTTTTCATTGTCGCTATTGATTTTTACTTCAATGGGCTCTTCCAACAAGGAAGAAGCTTGCTGGTAGC 401 ACTTGCTACCCTGAGTTCATCCAGGCCCAACTGTGAGCAAGGAGCACAAGCCACAAGTCTTCCAGAGGATGCTTGATTCC 481 AGTGGTTCTGCTTCAAGGCTTCCACTGCAAAACACTAAAGATCCAAGAAGGCCTTCATGGCCCCAGCAGGCCGGATCGGT 561 ACTGTATCAAGTCATGGCAGGTACAGTAGGATAAGCCACTCTGTCCCTTCCTGGGCAAAGAAGAAACGGAGGGGATGGAA 641 TTCTTCCTTAGACTTACTTTTGTAAAAATGTCCCCACGGTACTTACTCCCCACTGATGGACCAGTGGTTTCCAGTCATGA 721 GCGTTAGACTGACTTGTTTGTCTTCCATTCCATTGTTTTGAAACTCAGTATGCTGCCCCTGTCTTGCTGTCATGAAATCA 801 GCAAGAGAGGATGACACATCAAATAATAACTCGGATTCCAGCCCACATTGGATTCATCAGCATTTGGACCAATAGCCCAC 881 AGCTGAGAATGTGGAATACCTAAGGATAGCACCGCTTTTGTTCTCGCAAAAACGTATCTCCTAATTTGAGGCTCAGATGA 961 AATGCATCAGGTCCTTTGGGGCATAGATCAGAAGACTACAAAAATGAAGCTGCTCTGAAATCTCCTTTAGCCATCACCCC 1041 AACCCCCCAAAATTAGTTTGTGTTACTTATGGAAGATAGTTTTCTCCTTTTACTTCACTTCAAAAGCTTTTTACTCAAAG 1121 AGTATATGTTCCCTCCAGGTCAGCTGCCCCCAAACCCCCTCCTTACGCTTTGTCACACAAAAAGTGTCTCTGCCTTGAGT 1201 CATCTATTCAAGCACTTACAGCTCTGGCCACAACAGGGCATTTTACAGGTGCGAATGACAGTAGCATTATGAGTAGTGTG 1281 GAATTCAGGTAGTAAATATGAAACTAGGGTTTGAAATTGATAATGCTTTCACAACATTTGCAGATGTTTTAGAAGGAAAA 1361 AAGTTCCTTCCTAAAATAATTTCTCTACAATTGGAAGATTGGAAGATTCAGCTAGTTAGGAGCCCACCTTTTTTCCTAAT 1441 CTGTGTGTGCCCTGTAACCTGACTGGTTAACAGCAGTCCTTTGTAAACAGTGTTTTAAACTCTCCTAGTCAATATCCACC 1521 CCATCCAATTTATCAAGGAAGAAATGGTTCAGAAAATATTTTCAGCCTACAGTTATGTTCAGTCACACACACATACAAAA 1601 TGTTCCTTTTGCTTTTAAAGTAATTTTTGACTCCCAGATCAGTCAGAGCCCCTACAGCATTGTTAAGAAAGTATTTGATT 1681 TTTGTCTCAATGAAAATAAAACTATATTCATTTCCACTCTATTATGCTCTCAAATACCCCTAAGCATCTATACTAGCCTG 1761 GTATGGGTATGAAAGATACAAAGATAAATAAAACATAGTCCCTGATTCTAAGAAATTCACAATTTAGCAAAGGAAATGGA 1841 CTCATAGATGCTAACCTTAAAACAACGTGACAAATGCCAGACAGGACCCATCAGCCAGGCACTGTGAGAGCACAGAGCAG 1921 GGAGGTTGGGTCCTGCCTGAGGAGACCTGGAAGGGAGGCCTCACAGGAGGATGACCAGGTCTCAGTCAGCGGGGAGGTGG 2001 AAAGTGCAGGTGCATCAGGGGCACCCTGACCGAGGAAACAGCTGCCAGAGGCCTCCACTGCTAAAGTCCACATAAGGCTG 2081 AGGTCAGTCACCCTAAACAACCTGCTCCCTCTAAGCCAGGGGATGAGCTTGGAGCATCCCACAAGTTCCCTAAAAGTTGC 2161 AGCCCCCAGGGGGATTTTGAGCTATCATCTCTGCACATGCTTAGTGAGAAGACTACACAACATTTCTAAGAATCTGAGAT 2241 TTTATATTGTCAGTTAACCACTTTCATTATTCATTCACCTCAGGACATGCAGAAATATTTCAGTCAGAACTGGGAAACAG 2321 AAGGACCTACATTCTGCTGTCACTTATGTGTCAAGAAGCAGATGATCGATGAGGCAGGTCAGTTGTAAGTGAGTCACATT 2401 GTAGCATTAAATTCTAGTATTTTTGTAGTTTGAAACAGTAACTTAATAAAAGAGCAAAAGCTAAAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | PC3 , DU145 | ||||||
Disease | 1956.0 | ||||||
Location of target site | 3'UTR | ||||||
Original Description (Extracted from the article) |
...
"EGFR was significantly lowered in both DU145 and PC3 cell lines 72 h after transfection of miR-133a/b
... - Tao J; Wu D; Xu B; Qian W; Li P; Lu Q; Yin et al., 2012, Oncology reports. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Tao J; Wu D; Xu B; Qian W; Li P; Lu Q; Yin et al. - Oncology reports, 2012
It has been shown that regulation of EGFR expression in prostate cancer cells is mostly at the transcriptional level. microRNA-133 (miR-133) has long been recognized as a muscle-specific miRNA which may regulate myoblast differentiation and participate in many myogenic diseases. Recently, it has been reported that miR-133 is also involved in other tumors, such as bladder cancer, esophageal cancer and may regulate cell motility in these cancer cells. In the present study, we examined the expression and effects of miR-133 in two hormone-insensitive prostate cancer cell lines. The expression of miR-133a and miR-133b were analyzed by quantitative RT-PCR. After transfection of miR-133a and miR-133b, cell viability assay, luciferase assay, western blot analysis, cell migration and invasion assay were conducted in Du145 and PC3 cells. In this study, we showed that miR133a and miR-133b are expressed at the detection limit in two hormone-insensitive prostate cancer cell lines, PC3 and DU145. Ectopic expression of miR-133 inhibited cell proliferation, migration and invasion in these cells. We also provide the first evidence that miR-133 may target EGFR. Our study provided the first glimpse of the functional role of miR-133 in two hormone-independent prostate cancer cell lines. These results may add to our knowledge on the molecular basis of prostate cancer progression.
LinkOut: [PMID: 22407299]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HeLa |
Disease | 1956.0 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan |
Original Description (Extracted from the article) |
...
"the EGFR is a target of miR-133a
... - Lee SY; Ham O; Cha MJ; Song BW; Choi E; Kim et al., 2013, Biomaterials. |
Article |
- Lee SY; Ham O; Cha MJ; Song BW; Choi E; Kim et al. - Biomaterials, 2013
Human bone marrow-derived mesenchymal stem cells (hMSCs) are an attractive candidate for cell therapy in heart disease. Low survival and incomplete electromechanical integration between resident cardiomyocytes and transplanted hMSCs remain unsolved. In order for an infarcted heart to tolerate transplantation, differentiation capacity in stem cells must be reinforced. In this study, we found that compound 56, an epidermal growth factor receptor (EGFR) inhibitor, promotes cardiogenic differentiation of hMSCs and the transplantation of hMSCs treated with compound 56 resulted in enhancement of heart functions. Furthermore, hMSCs transfected with microRNA-133a (miR-133a), which targets EGFR, were observed to express cardiac-specific markers. We also discovered that luciferase activity is exclusively decreased by targeting EGFR in hMSCs transfected with miR-133a mimic. These results suggest that EGFR plays a key role in the regulation of cardiogenic differentiation in hMSCs.
LinkOut: [PMID: 23069713]
|
Experimental Support 3 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | HBL-100 , MCF-7 |
Location of target site | 3'UTR |
Tools used in this research | DIANA-microT , TargetScan |
Original Description (Extracted from the article) |
...
These data manifest that the miR-133a functions by directly targeting to the 3芒鈧鈩UTR of EGFR.
... - Cui W; Zhang S; Shan C; Zhou L; Zhou Z, 2013, The FEBS journal. |
Article |
- Cui W; Zhang S; Shan C; Zhou L; Zhou Z - The FEBS journal, 2013
microRNAs are small, highly conserved, non-coding RNAs that regulate gene expression of target mRNAs through cleavage or translational inhibition, and are widely involved in carcinogenesis and cancer development. In this study, the expression profile of microRNA-133a (miR-133a) was examined in breast cancer cells and breast cancer tissues. The results showed that expression of miR-133a in both breast cancer cells and breast cancer tissues was significantly down-regulated. Over-expression of miR-133a in tumor cells arrested the cell cycle by drastically decreasing the G2 /S phase and retarded the newly synthesized DNA, suggesting a regulatory role for miR-133a in proliferation of breast cancer cells. Bioinformatics prediction showed that epidermal growth factor receptor (EGFR) is a potential target for miR-133a. A dual luciferase reporter gene assay showed that miR-133a bound to the 3' UTR of EGFR but not a mutated 3' UTR, thereby down-regulating the protein expression level. Accordingly, we found that expression of EGFR protein decreased with increased expression of miR-133a in MCF-7 and MDA-MB-231 cells. Over-expression of miR-133a in breast cancer cells resulted in suppression of the level of phosphorylated Akt protein (p-Akt) and inhibition of p-Akt nuclear translocation. These results demonstrate that miR-133a, which may act as a tumor suppressor in breast cancer, regulates the cell cycle and proliferation in tumorigenesis by targeting EGFR through the downstream signal molecule Akt. Overall, these results show that miR-133a may be used as biomarker and/or therapeutic target for diagnosis and therapy of breast cancer.
LinkOut: [PMID: 23786162]
|
Experimental Support 4 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | A549 , H1299 |
Disease | non-small cell lung carcinoma |
Location of target site | 3'UTR |
Original Description (Extracted from the article) |
...
MiR133a is downregulated in malignant lung cancer cells and inhibits the cell invasive capacity
... - Wang LK; Hsiao TH; Hong TM; Chen HY; Kao et al., 2014, PloS one. |
Article |
- Wang LK; Hsiao TH; Hong TM; Chen HY; Kao et al. - PloS one, 2014
Non-small cell lung cancers (NSCLCs) cause high mortality worldwide, and the cancer progression can be activated by several genetic events causing receptor dysregulation, including mutation or amplification. MicroRNAs are a group of small non-coding RNA molecules that function in gene silencing and have emerged as the fine-tuning regulators during cancer progression. MiR-133a is known as a key regulator in skeletal and cardiac myogenesis, and it acts as a tumor suppressor in various cancers. This study demonstrates that miR-133a expression negatively correlates with cell invasiveness in both transformed normal bronchial epithelial cells and lung cancer cell lines. The oncogenic receptors in lung cancer cells, including insulin-like growth factor 1 receptor (IGF-1R), TGF-beta receptor type-1 (TGFBR1), and epidermal growth factor receptor (EGFR), are direct targets of miR-133a. MiR-133a can inhibit cell invasiveness and cell growth through suppressing the expressions of IGF-1R, TGFBR1 and EGFR, which then influences the downstream signaling in lung cancer cell lines. The cell invasive ability is suppressed in IGF-1R- and TGFBR1-repressed cells and this phenomenon is mediated through AKT signaling in highly invasive cell lines. In addition, by using the in vivo animal model, we find that ectopically-expressing miR-133a dramatically suppresses the metastatic ability of lung cancer cells. Accordingly, patients with NSCLCs who have higher expression levels of miR-133a have longer survival rates compared with those who have lower miR-133a expression levels. In summary, we identified the tumor suppressor role of miR-133a in lung cancer outcome prognosis, and we demonstrated that it targets several membrane receptors, which generally produce an activating signaling network during the progression of lung cancer.
LinkOut: [PMID: 24816813]
|
Experimental Support 5 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Disease | cervical cancer |
Location of target site | 3'UTR |
Tools used in this research | miRanda , TargetScan |
Original Description (Extracted from the article) |
...
The epidermal growth factor receptor (EGFR) was confirmed to be a direct target of miR-133a in cervical cancer cells using luciferase assay and western blotting
... - Song X; Shi B; Huang K; Zhang W, 2015, Oncology reports. |
Article |
- Song X; Shi B; Huang K; Zhang W - Oncology reports, 2015
MicroRNAs (miRNAs) are small non-coding RNAs that play critical roles in cervical carcinogenesis and progression. microRNA-133a (miR-133a) has been reported to play a tumor-suppressor role in a range of cancers. However, the role and underlying molecular mechanism of miR-133a in cervical cancer have not been investigated. In the present study, we investigated the role of miR-133a in the tumorigenicity of cervical cancer cells in vivo and in vitro. The expression of miR-133a was investigated using real-time reverse transcription-polymerase chain reaction (qRT-PCR) in 30 cervical specimens and matched adjacent normal tissues and cervical cancer cell lines. We found that the expression level of miR133a was significantly downregulated in cervical cancer tissues and cervical cancer cell lines, and the aberrant expression of miR-133a was correlated with lymph node metastasis, histological grade and FIGO stage. The role of miR-133a in tumorigenicity of cervical cancer cells was assessed by the restoration of miR-133a. We found that restoration of miR133a inhibited cell proliferation, colony formation, migration and invasion, promoted cell apoptosis in vitro and suppressed tumorigenicity in vivo. The epidermal growth factor receptor (EGFR) was confirmed to be a direct target of miR-133a in cervical cancer cells using luciferase assay and western blotting. Restoration of miR-133a inhibited EGFR expression and activated the AKT and ERK signaling pathways. These results showed that miR-133a suppresses cervical cancer growth in vitro and in vivo through targeting EGFR, suggesting that miR-133a can be a potential target for the treatment of cervical cancer.
LinkOut: [PMID: 26134491]
|
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
122 hsa-miR-133a-3p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT000325 | RHOA | ras homolog family member A | 1 | 2 | ||||||||
MIRT000327 | CDC42 | cell division cycle 42 | 4 | 2 | ||||||||
MIRT000328 | ERG | ERG, ETS transcription factor | 1 | 1 | ||||||||
MIRT000329 | HCN4 | hyperpolarization activated cyclic nucleotide gated potassium channel 4 | 2 | 1 | ||||||||
MIRT000330 | UCP2 | uncoupling protein 2 | 2 | 2 | ||||||||
MIRT000331 | KRT7 | keratin 7 | 2 | 2 | ||||||||
MIRT001203 | CACNA1C | calcium voltage-gated channel subunit alpha1 C | 3 | 1 | ||||||||
MIRT001204 | HCN2 | hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 | 4 | 2 | ||||||||
MIRT001816 | PKM | pyruvate kinase, muscle | 1 | 1 | ||||||||
MIRT001986 | CASP9 | caspase 9 | 3 | 3 | ||||||||
MIRT002925 | KCNQ1 | potassium voltage-gated channel subfamily Q member 1 | 4 | 1 | ||||||||
MIRT003542 | FSCN1 | fascin actin-bundling protein 1 | 5 | 4 | ||||||||
MIRT004831 | KCNH2 | potassium voltage-gated channel subfamily H member 2 | 4 | 1 | ||||||||
MIRT005604 | TAGLN2 | transgelin 2 | 5 | 4 | ||||||||
MIRT005813 | LASP1 | LIM and SH3 protein 1 | 3 | 2 | ||||||||
MIRT006571 | PNP | purine nucleoside phosphorylase | 4 | 2 | ||||||||
MIRT006680 | MSN | moesin | 2 | 1 | ||||||||
MIRT007032 | EGFR | epidermal growth factor receptor | 3 | 5 | ||||||||
MIRT007088 | VKORC1 | vitamin K epoxide reductase complex subunit 1 | 1 | 1 | ||||||||
MIRT007383 | PRDM16 | PR/SET domain 16 | 1 | 2 | ||||||||
MIRT021693 | TPM1 | tropomyosin 1 | 1 | 1 | ||||||||
MIRT021695 | FBN1 | fibrillin 1 | 1 | 1 | ||||||||
MIRT021696 | FAM120C | family with sequence similarity 120C | 1 | 1 | ||||||||
MIRT021697 | BCAN | brevican | 1 | 1 | ||||||||
MIRT021698 | TCTEX1D2 | Tctex1 domain containing 2 | 1 | 1 | ||||||||
MIRT021699 | ARL6IP1 | ADP ribosylation factor like GTPase 6 interacting protein 1 | 1 | 1 | ||||||||
MIRT021700 | RFT1 | RFT1 homolog | 1 | 1 | ||||||||
MIRT021701 | SENP1 | SUMO1/sentrin specific peptidase 1 | 1 | 1 | ||||||||
MIRT021702 | SMIM14 | small integral membrane protein 14 | 1 | 1 | ||||||||
MIRT021703 | PRELID1 | PRELI domain containing 1 | 1 | 1 | ||||||||
MIRT021704 | CNN2 | calponin 2 | 3 | 3 | ||||||||
MIRT021705 | ARPC5 | actin related protein 2/3 complex subunit 5 | 4 | 2 | ||||||||
MIRT021706 | FTL | ferritin light chain | 2 | 2 | ||||||||
MIRT021707 | CERS2 | ceramide synthase 2 | 1 | 1 | ||||||||
MIRT021708 | SEC61B | Sec61 translocon beta subunit | 1 | 1 | ||||||||
MIRT021709 | PLEKHA3 | pleckstrin homology domain containing A3 | 1 | 1 | ||||||||
MIRT021710 | EGFL7 | EGF like domain multiple 7 | 1 | 1 | ||||||||
MIRT021711 | VEGFA | vascular endothelial growth factor A | 1 | 1 | ||||||||
MIRT021712 | PIK3R2 | phosphoinositide-3-kinase regulatory subunit 2 | 1 | 1 | ||||||||
MIRT021713 | RGS3 | regulator of G protein signaling 3 | 1 | 1 | ||||||||
MIRT021714 | COL1A1 | collagen type I alpha 1 chain | 4 | 1 | ||||||||
MIRT021715 | GSTP1 | glutathione S-transferase pi 1 | 2 | 1 | ||||||||
MIRT035537 | SP1 | Sp1 transcription factor | 2 | 2 | ||||||||
MIRT035579 | KLF15 | Kruppel like factor 15 | 1 | 1 | ||||||||
MIRT045837 | NR4A2 | nuclear receptor subfamily 4 group A member 2 | 1 | 1 | ||||||||
MIRT052647 | BCL2L1 | BCL2 like 1 | 4 | 2 | ||||||||
MIRT052648 | MCL1 | MCL1, BCL2 family apoptosis regulator | 4 | 2 | ||||||||
MIRT053333 | RFFL | ring finger and FYVE like domain containing E3 ubiquitin protein ligase | 4 | 1 | ||||||||
MIRT054310 | IGF1R | insulin like growth factor 1 receptor | 3 | 2 | ||||||||
MIRT055599 | FAM160B1 | family with sequence similarity 160 member B1 | 2 | 2 | ||||||||
MIRT081957 | UBA2 | ubiquitin like modifier activating enzyme 2 | 4 | 1 | ||||||||
MIRT437400 | MMP14 | matrix metallopeptidase 14 | 3 | 1 | ||||||||
MIRT437953 | ANXA2 | annexin A2 | 4 | 1 | ||||||||
MIRT437954 | SNX30 | sorting nexin family member 30 | 4 | 1 | ||||||||
MIRT437955 | SGMS2 | sphingomyelin synthase 2 | 4 | 1 | ||||||||
MIRT438719 | PDLIM5 | PDZ and LIM domain 5 | 3 | 1 | ||||||||
MIRT452802 | PACS2 | phosphofurin acidic cluster sorting protein 2 | 2 | 2 | ||||||||
MIRT462823 | BCL3 | B-cell CLL/lymphoma 3 | 2 | 2 | ||||||||
MIRT468494 | SESN2 | sestrin 2 | 2 | 2 | ||||||||
MIRT477714 | EFHD2 | EF-hand domain family member D2 | 2 | 2 | ||||||||
MIRT483852 | EMID1 | EMI domain containing 1 | 2 | 2 | ||||||||
MIRT490039 | PRRT2 | proline rich transmembrane protein 2 | 2 | 2 | ||||||||
MIRT491349 | CDKN1A | cyclin dependent kinase inhibitor 1A | 2 | 4 | ||||||||
MIRT504443 | MC2R | melanocortin 2 receptor | 2 | 2 | ||||||||
MIRT505701 | SESN3 | sestrin 3 | 2 | 2 | ||||||||
MIRT513521 | RHOQ | ras homolog family member Q | 2 | 4 | ||||||||
MIRT517423 | HIST2H2AC | histone cluster 2 H2A family member c | 2 | 2 | ||||||||
MIRT526599 | DCAKD | dephospho-CoA kinase domain containing | 2 | 2 | ||||||||
MIRT528904 | THBS2 | thrombospondin 2 | 2 | 2 | ||||||||
MIRT533060 | ZBTB37 | zinc finger and BTB domain containing 37 | 2 | 2 | ||||||||
MIRT534126 | SNX33 | sorting nexin 33 | 2 | 2 | ||||||||
MIRT534700 | RNF103-CHMP3 | RNF103-CHMP3 readthrough | 2 | 4 | ||||||||
MIRT535732 | MYPN | myopalladin | 2 | 2 | ||||||||
MIRT538529 | CHMP3 | charged multivesicular body protein 3 | 2 | 4 | ||||||||
MIRT550878 | IBA57 | IBA57 homolog, iron-sulfur cluster assembly | 2 | 2 | ||||||||
MIRT551260 | PSMG1 | proteasome assembly chaperone 1 | 2 | 2 | ||||||||
MIRT551981 | UGT2B10 | UDP glucuronosyltransferase family 2 member B10 | 2 | 2 | ||||||||
MIRT553866 | SYAP1 | synapse associated protein 1 | 2 | 2 | ||||||||
MIRT558810 | CDK5R1 | cyclin dependent kinase 5 regulatory subunit 1 | 2 | 2 | ||||||||
MIRT559367 | ATP13A3 | ATPase 13A3 | 2 | 2 | ||||||||
MIRT560941 | ZFP28 | ZFP28 zinc finger protein | 2 | 2 | ||||||||
MIRT565461 | SUPT16H | SPT16 homolog, facilitates chromatin remodeling subunit | 2 | 2 | ||||||||
MIRT566234 | PTMA | prothymosin, alpha | 2 | 2 | ||||||||
MIRT568217 | C11orf24 | chromosome 11 open reading frame 24 | 2 | 2 | ||||||||
MIRT608912 | NCDN | neurochondrin | 2 | 6 | ||||||||
MIRT613229 | CCDC39 | coiled-coil domain containing 39 | 2 | 2 | ||||||||
MIRT623563 | ITPKB | inositol-trisphosphate 3-kinase B | 2 | 2 | ||||||||
MIRT637224 | TMEM59 | transmembrane protein 59 | 2 | 2 | ||||||||
MIRT641669 | CCNI | cyclin I | 2 | 2 | ||||||||
MIRT644440 | ALDOC | aldolase, fructose-bisphosphate C | 2 | 2 | ||||||||
MIRT644755 | TXNRD3NB | thioredoxin reductase 3 neighbor | 2 | 2 | ||||||||
MIRT646711 | PDE1A | phosphodiesterase 1A | 2 | 2 | ||||||||
MIRT647577 | RBMXL1 | RNA binding motif protein, X-linked like 1 | 2 | 2 | ||||||||
MIRT647760 | RNF168 | ring finger protein 168 | 2 | 2 | ||||||||
MIRT649267 | C17orf64 | chromosome 17 open reading frame 64 | 2 | 2 | ||||||||
MIRT651238 | ZMAT4 | zinc finger matrin-type 4 | 2 | 2 | ||||||||
MIRT652146 | TRIM71 | tripartite motif containing 71 | 2 | 2 | ||||||||
MIRT657168 | IP6K1 | inositol hexakisphosphate kinase 1 | 2 | 2 | ||||||||
MIRT668302 | FOSL2 | FOS like 2, AP-1 transcription factor subunit | 2 | 2 | ||||||||
MIRT687546 | MLEC | malectin | 2 | 2 | ||||||||
MIRT690857 | PLEKHG2 | pleckstrin homology and RhoGEF domain containing G2 | 2 | 2 | ||||||||
MIRT697060 | PSMC4 | proteasome 26S subunit, ATPase 4 | 2 | 2 | ||||||||
MIRT699725 | SERPINH1 | serpin family H member 1 | 2 | 2 | ||||||||
MIRT700858 | PER2 | period circadian clock 2 | 2 | 2 | ||||||||
MIRT705068 | C4orf29 | abhydrolase domain containing 18 | 2 | 2 | ||||||||
MIRT709496 | ANGPT4 | angiopoietin 4 | 2 | 2 | ||||||||
MIRT713925 | PIGR | polymeric immunoglobulin receptor | 2 | 2 | ||||||||
MIRT716058 | SFTPB | surfactant protein B | 2 | 2 | ||||||||
MIRT716724 | APOL6 | apolipoprotein L6 | 2 | 2 | ||||||||
MIRT721677 | CMTM4 | CKLF like MARVEL transmembrane domain containing 4 | 2 | 2 | ||||||||
MIRT723379 | NFAM1 | NFAT activating protein with ITAM motif 1 | 2 | 2 | ||||||||
MIRT731340 | IGF1 | insulin like growth factor 1 | 1 | 1 | ||||||||
MIRT731591 | ZEB1 | zinc finger E-box binding homeobox 1 | 1 | 1 | ||||||||
MIRT732526 | PTBP1 | polypyrimidine tract binding protein 1 | 2 | 0 | ||||||||
MIRT732527 | KDM5C | lysine demethylase 5C | 2 | 0 | ||||||||
MIRT732589 | BCL2 | BCL2, apoptosis regulator | 2 | 0 | ||||||||
MIRT732590 | CASP3 | caspase 3 | 2 | 0 | ||||||||
MIRT733594 | PPP2CA | protein phosphatase 2 catalytic subunit alpha | 3 | 0 | ||||||||
MIRT735355 | MB | myoglobin | 1 | 0 | ||||||||
MIRT735744 | CDCA8 | cell division cycle associated 8 | 3 | 0 | ||||||||
MIRT736984 | SET | SET nuclear proto-oncogene | 1 | 0 | ||||||||
MIRT737550 | TGFB1 | transforming growth factor beta 1 | 4 | 0 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|